help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Published ahead of print on July 8, 2004, doi:10.1164/rccm.200311-1488OC
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
200311-1488OCv1
170/8/851    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Leigh, R.
Right arrow Articles by Inman, M. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Leigh, R.
Right arrow Articles by Inman, M. D.
American Journal of Respiratory and Critical Care Medicine Vol 170. pp. 851-856, (2004)
© 2004 American Thoracic Society
doi: 10.1164/rccm.200311-1488OC

Is Interleukin-13 Critical in Maintaining Airway Hyperresposiveness in Allergen-challenged Mice?

Richard Leigh, Russ Ellis, Jennifer Wattie, Debra D. Donaldson and Mark D. Inman

Firestone Institute for Respiratory Health, St. Joseph's Healthcare, McMaster University, Hamilton, Ontario, Canada; and Wyeth Research, Wyeth Pharmaceuticals Inc., Cambridge, MA

Correspondence and requests for reprints should be addressed to Mark D. Inman, M.D., Ph.D., Firestone Institute for Respiratory Health, St. Joseph's Healthcare, 50 Charlton Avenue East, Hamilton, ON, L8N 4A6 Canada. E-mail: inmanma{at}mcmaster.ca

Interleukin (IL)-13 is regarded as being a central effector in the pathophysiology of airway hyperresponsiveness. We have described a mouse model in which chronic allergen exposure results in sustained airway hyperresponsiveness and aspects of airway remodeling, and here sought to demonstrate that this component of airway hyperresponsiveness is independent of biologically active IL-13. Sensitized mice were subjected to either brief or chronic periods of allergen exposure and studied 24 hours after brief or 4 weeks after chronic allergen inhalation. A soluble murine anti–IL-13 receptor fusion protein that specifically binds to and neutralizes IL-13 was given daily during the 4 days before the day of outcome measurements in both protocols. Outcome measurements included airway responses to intravenous methacholine, bronchoalveolar lavage fluid cell counts, and airway morphometry. Compared with the saline control, brief allergen challenge resulted in airway hyperresponsiveness, which was prevented by anti–IL-13 treatment. Chronic allergen challenge resulted in sustained airway hyperresponsiveness and indices of airway remodeling; IL-13 blockade failed to reverse this sustained airway hyperresponsiveness. These results confirm that IL-13 is critical for the development of airway hyperresponsiveness associated with brief allergen exposure, but is not necessary to maintain the sustained airway hyperresponsiveness associated with airway remodeling.

Key Words: airway inflammation • allergic disease • asthma • bronchial hyperreactivity




This article has been cited by other articles:


Home page
 DMMHome page
F. A. DiGiovanni, R. Ellis, J. Wattie, J. A. Hirota, D. S. Southam, and M. D. Inman
Concurrent dual allergen exposure and its effects on airway hyperresponsiveness, inflammation and remodeling in mice
Dis. Model. Mech., May 1, 2009; 2(5-6): 275 - 282.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
J. Kearley, K. F. Buckland, S. A. Mathie, and C. M. Lloyd
Resolution of Allergic Inflammation and Airway Hyperreactivity Is Dependent upon Disruption of the T1/ST2-IL-33 Pathway
Am. J. Respir. Crit. Care Med., May 1, 2009; 179(9): 772 - 781.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
D. S. Southam, R. Ellis, J. Wattie, W. Glass, and M. D. Inman
Goblet Cell Rebound and Airway Dysfunction with Corticosteroid Withdrawal in a Mouse Model of Asthma
Am. J. Respir. Crit. Care Med., December 1, 2008; 178(11): 1115 - 1122.
[Abstract] [Full Text] [PDF]

Home page
 DMMHome page
A. T. Nials and S. Uddin
Mouse models of allergic asthma: acute and chronic allergen challenge
Dis. Model. Mech., November 1, 2008; 1(4-5): 213 - 220.
[Abstract] [Full Text] [PDF]

Home page
 Biol Res NursHome page
M. Antosova, A. Strapkova, and T. Turcan
Exogenous Irritant-Induced Airway Hyperreactivity and Inhibition of Soluble Guanylyl Cyclase
Biol Res Nurs, October 1, 2008; 10(2): 93 - 101.
[Abstract] [PDF]

Home page
 Eur Respir JHome page
E. H. Walters, D. W. Reid, D. P. Johns, and C. Ward
Nonpharmacological and pharmacological interventions to prevent or reduce airway remodelling
Eur. Respir. J., September 1, 2007; 30(3): 574 - 588.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
Y. Ma, K. T. HayGlass, A. B. Becker, Y. Fan, X. Yang, S. Basu, G. Srinivasan, F. E. R. Simons, A. J. Halayko, and Z. Peng
Novel Recombinant Interleukin-13 Peptide-based Vaccine Reduces Airway Allergic Inflammatory Responses in Mice
Am. J. Respir. Crit. Care Med., September 1, 2007; 176(5): 439 - 445.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
P. Forsythe, M. D. Inman, and J. Bienenstock
Oral Treatment with Live Lactobacillus reuteri Inhibits the Allergic Airway Response in Mice
Am. J. Respir. Crit. Care Med., March 15, 2007; 175(6): 561 - 569.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
Y. Tabata, W. Chen, M. R. Warrier, A. M. Gibson, M. O. Daines, and G. K. K. Hershey
Allergy-Driven Alternative Splicing of IL-13 Receptor {alpha}2 Yields Distinct Membrane and Soluble Forms
J. Immunol., December 1, 2006; 177(11): 7905 - 7912.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
E. Careau, L.-I. Proulx, P. Pouliot, A. Spahr, V. Turmel, and E. Y. Bissonnette
Antigen sensitization modulates alveolar macrophage functions in an asthma model
Am J Physiol Lung Cell Mol Physiol, May 1, 2006; 290(5): L871 - L879.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
G. Yang, L. Li, A. Volk, E. Emmell, T. Petley, J. Giles-Komar, P. Rafferty, M. Lakshminarayanan, D. E. Griswold, P. J. Bugelski, et al.
Therapeutic Dosing with Anti-Interleukin-13 Monoclonal Antibody Inhibits Asthma Progression in Mice
J. Pharmacol. Exp. Ther., April 1, 2005; 313(1): 8 - 15.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
L. Fabbri, S. P. Peters, I. Pavord, S. E. Wenzel, S. C. Lazarus, W. MacNee, F. Lemaire, and E. Abraham
Allergic Rhinitis, Asthma, Airway Biology, and Chronic Obstructive Pulmonary Disease in AJRCCM in 2004
Am. J. Respir. Crit. Care Med., April 1, 2005; 171(7): 686 - 698.
[Full Text] [PDF]

Home page
 Am. J. Respir. Cell Mol. Bio.Home page
M. M. Kelly, R. Leigh, P. Bonniaud, R. Ellis, J. Wattie, M. J. Smith, G. Martin, M. Panju, M. D. Inman, and J. Gauldie
Epithelial Expression of Profibrotic Mediators in a Model of Allergen-Induced Airway Remodeling
Am. J. Respir. Cell Mol. Biol., February 1, 2005; 32(2): 99 - 107.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 2004 American Thoracic Society 		  Tobacco